The University of Chicago Header Logo

Anand Patel

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
ORCID ORCID Icon0000-0002-0296-8686 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.

    Collapse Biography 
    Collapse education and training
    Northwestern University, Evanston, ILBA06/2010Economics
    University of Missouri School of Medicine, Columbia, MOMD05/2014Medicine
    McGaw Medical Center of Northwestern University, Chicago, ILResidency06/2017Internal Medicine
    McGaw Medical Center of Northwestern University, Chicago, ILChief Residency06/2018Internal Medicine
    University of Chicago, Chicago, ILFellowship06/2021Hematology-Oncology

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77. PMID: 37801340.
      Citations:    Fields:    Translation:Humans
    2. Johnston H, Rahmani Youshanlouei H, Osei C, Patel AA, DuVall AS, Wang P, Wanjari P, Segal JP, Venkataraman G, Cheng JX, Gurbuxani S, Lager AM, Fitzpatrick C, Thirman MJ, Nawas MT, Liu H, Drazer MW, Odenike O, Larson RA, Stock W, Saygin C, Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171. PMID: 38039510; PMCID: PMC10787242.
      Citations:    Fields:    Translation:Humans
    3. Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27. PMID: 38150184.
      Citations:    Fields:    
    4. Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, Stock W, Patel AA. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2023 Dec 10. PMID: 38073116.
      Citations:    Fields:    
    5. Fan H, Xia S, Xiang J, Li Y, Ross MO, Lim SA, Yang F, Tu J, Xie L, Dougherty U, Zhang FQ, Zheng Z, Zhang R, Wu R, Dong L, Su R, Chen X, Althaus T, Riedell PA, Jonker PB, Muir A, Lesinski GB, Rafiq S, Dhodapkar MV, Stock W, Odenike O, Patel AA, Opferman J, Tsuji T, Matsuzaki J, Shah H, Faubert B, Elf SE, Layden B, Bissonnette BM, He YY, Kline J, Mao H, Odunsi K, Gao X, Chi H, He C, Chen J. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043. PMID: 37993715; PMCID: PMC10686835.
      Citations:    Fields:    Translation:HumansAnimalsCells
    6. Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505. PMID: 37647601; PMCID: PMC10632668.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, Ananthanarayanan V, Vincent TL, DuVall A, Patel AA, Chen Y, Tan F, Anthony SP, Chen Y, Shen Y, Odenike O, Teachey DT, Kee BL, LaBelle J, Stock W. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161. PMID: 37363966; PMCID: PMC10425730.
      Citations: 1     Fields:    Translation:HumansCells
    8. Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, DeAngelo DJ, Lathan CS, Abel GA. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2023 Aug 10. PMID: 37560812.
      Citations:    Fields:    
    9. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
      Citations:    Fields:    Translation:Humans
    10. Abaza Y, Patel AA. Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in? Cancer J. 2023 May-Jun 01; 29(3):188-194. PMID: 37195775.
      Citations:    Fields:    Translation:Humans
    11. Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023 04; 37(4):799-806. PMID: 36807649.
      Citations: 8     Fields:    Translation:Humans
    12. Chen EC, Johnston H, Patel AA. Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55. PMID: 36705855.
      Citations:    Fields:    Translation:Humans
    13. Patel AA, Odenike O. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309. PMID: 36907766.
      Citations:    Fields:    Translation:Humans
    14. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 03 15; 129(6):934-945. PMID: 36545710.
      Citations: 1     Fields:    Translation:Humans
    15. Cooperrider JH, Shukla N, Nawas MT, Patel AA. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85. PMID: 36223559; PMCID: PMC10476749.
      Citations: 1     Fields:    Translation:Humans
    16. Alban J, DuVall A, Gurbuxani S, Stock W, Patel AA. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353. PMID: 36240471; PMCID: PMC9616637.
      Citations:    Fields:    Translation:HumansCells
    17. Abraham IE, Rauscher GH, Patel AA, Pearse WB, Rajakumar P, Burkart M, Aleem A, Dave A, Bharadwaj S, Paydary K, Acevedo-Mendez M, Goparaju K, Gomez R, Carlson K, Tsai SB, Quigley JG, Galvin JP, Zia M, Larson ML, Berg S, Stock W, Altman JK, Khan I. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226. PMID: 35061876; PMCID: PMC9710198.
      Citations: 18     Fields:    Translation:Humans
    18. Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 07; 97(7):E232-E235. PMID: 35338673.
      Citations: 13     Fields:    Translation:Humans
    19. Phadke VK, Jagannath AD, Patel AA, Sherman SV. Over the Threshold: an Exercise in Clinical Reasoning. J Gen Intern Med. 2022 04; 37(5):1290-1294. PMID: 35075534; PMCID: PMC8971242.
      Citations:    Fields:    Translation:Humans
    20. Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148. PMID: 34492705; PMCID: PMC8945635.
      Citations: 6     Fields:    Translation:HumansCells
    21. Kacew AJ, Jacobson S, Sheade J, Patel AA, Hlubocky FJ, Lee NK, Henderson TO, Schneider JA, Strohbehn GW. Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers. J Adolesc Young Adult Oncol. 2022 06; 11(3):284-289. PMID: 34403603.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    22. Atassi G, Manesh R, Patel A, Tariq H, Puri A. The Phantom Menace: Immunodeficiency-Associated Disease in an Immunocompetent Patient. Am J Med. 2021 12; 134(12):1555-1557. PMID: 34273281.
      Citations:    Fields:    Translation:Humans
    23. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420. PMID: 35844676; PMCID: PMC9175801.
      Citations: 2     
    24. Minter DJ, Patel A, Ganeshan S, Nematollahi S. Medical Communities Go Virtual. J Hosp Med. 2021 06; 16(6):378-380. PMID: 33147130.
      Citations: 2     Fields:    
    25. Patel AA, Cahill K, Saygin C, Odenike O. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271. PMID: 33904891; PMCID: PMC8095139.
      Citations: 10     Fields:    Translation:Humans
    26. Abraham IE, Patel AA, Wang H, Galvin JP, Frankfurt O, Liu L, Khan I. Impact of race on outcomes in intermediate-risk acute myeloid leukemia. Cancer Causes Control. 2021 Jul; 32(7):705-712. PMID: 33837498.
      Citations: 1     Fields:    Translation:Humans
    27. Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 08; 56(8):1998-2004. PMID: 33824440.
      Citations: 1     Fields:    Translation:HumansCells
    28. Kalas V, Johnson-Sasso C, Morency EG, Ji P, Manesh R, Patel AA. Paraneoplastic Thrombocytopenia. Am J Med. 2021 08; 134(8):976-979. PMID: 33621535.
      Citations:    Fields:    Translation:Humans
    29. Berk J, Olson AP, Geha RM, Patel A, Manesh R. Left Out in the Cold. J Hosp Med. 2021 02; 16(2):105-108. PMID: 32853136.
      Citations:    Fields:    Translation:Humans
    30. Patel AA, Odenike O. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449. PMID: 33275731; PMCID: PMC7727554.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    31. Patel AA, Odenike O. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418. PMID: 32780250.
      Citations: 10     Fields:    Translation:Humans
    32. Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048. PMID: 33259056.
      Citations: 6     Fields:    Translation:Humans
    33. Carll T, Patel A, Derman B, Hyjek E, Lager A, Wanjari P, Segal J, Odenike O, Fidai S, Arber D. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928. PMID: 33049052; PMCID: PMC7556145.
      Citations: 7     Fields:    Translation:Humans
    34. Russell SW, Desai SV, O'Rourke P, Ahuja N, Patel A, Myers CG, Zulman D, Sateia HF, Berkenblit GV, Johnson EN, Garibaldi BT. The genealogy of teaching clinical reasoning and diagnostic skill: the GEL Study. Diagnosis (Berl). 2020 08 27; 7(3):197-203. PMID: 32146439.
      Citations: 2     Fields:    Translation:Humans
    35. Russell SW, Ahuja N, Patel A, O'Rourke P, Desai SV, Garibaldi BT. Peabody's Paradox: Balancing Patient Care and Medical Education in a Pandemic. J Grad Med Educ. 2020 Jun; 12(3):264-268. PMID: 32595841; PMCID: PMC7301921.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    36. Patel AA, Thomas J, Rojek AE, Stock W. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57. PMID: 32468488.
      Citations: 9     Fields:    Translation:Humans
    37. Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 05 26; 4(10):2308-2316. PMID: 32453836; PMCID: PMC7252553.
      Citations: 9     Fields:    Translation:HumansCells
    38. Patel AA, Smith SM. Clinical and Biological Prognostic Factors in Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 08; 34(4):647-662. PMID: 32586571.
      Citations: 2     Fields:    Translation:Humans
    39. Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51. PMID: 32358888.
      Citations: 13     Fields:    Translation:Humans
    40. Singer BD, Goodwin AM, Patel AA, Vaughan DE. The Socrates Project for Difficult Diagnosis at Northwestern Medicine. J Hosp Med. 2020 02 01; 15(2):116-118. PMID: 31891565; PMCID: PMC7051183.
      Citations: 1     Fields:    Translation:Humans
    41. Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL. FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 08 09; 3(15). PMID: 30089730; PMCID: PMC6129129.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    42. Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013 May; 42(5):1516-22. PMID: 23546524.
      Citations: 30     Fields:    Translation:HumansCells
    43. Kumar GS, Chang W, Xie T, Patel A, Zhang Y, Wang GG, David G, Radhakrishnan I. Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1 subunits of the Rpd3S/Sin3S corepressor complex. J Mol Biol. 2012 Sep 28; 422(4):519-31. PMID: 22728643; PMCID: PMC3428507.
      Citations: 16     Fields:    Translation:HumansCells
    Patel's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (192)
    Explore
    _
    Co-Authors (32)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _